Anthocyanin supplementation improves anti-oxidative and anti-inflammatory capacity in a dose–response manner in subjects with dyslipidemia

Hanyue Zhang\textsuperscript{a,b}, Zhongliang Xu\textsuperscript{a,b}, Huiwen Zhao\textsuperscript{a,b}, Xu Wang\textsuperscript{a,b}, Juan Pang\textsuperscript{a,b}, Qing Li\textsuperscript{a,b}, Yan Yang\textsuperscript{b,c,d,∗∗}, Wenhua Ling\textsuperscript{a,b,c,∗}

\textsuperscript{a} Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong Province, PR China
\textsuperscript{b} Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong Province, PR China
\textsuperscript{c} Guangdong Engineering Technology Center of Nutrition Transformation, Guangzhou, Guangdong Province, PR China
\textsuperscript{d} Department of Nutrition, School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong Province, PR China

\textbf{ARTICLE INFO}

\textbf{Keywords:}
Anthocyanins
8-isoprostaglandinF\textsubscript{2\alpha}
8-Hydroxy-2′-deoxyguanosine
Interleukin-6
Randomized controlled trial

\textbf{ABSTRACT}

\textbf{Background:} Anthocyanins, one of the major plant bioactive substances, possess anti-oxidative and anti-inflammatory capacity. However, their dose–response relationship has remained unclear. The present study investigated the dose–response relationship of anthocyanins with oxidative stress and inflammation in subjects with dyslipidemia.

\textbf{Design:} and Participants: A total of 169 participants with dyslipidemia were randomly assigned to placebo (n = 43), anthocyanins 40 mg/day (n = 44), 80 mg/day (n = 40), or 320 mg/day (n = 42) groups. Urine 8-isoprostaglandin F\textsubscript{2\alpha} (8-iso-PGF\textsubscript{2\alpha}), 8-hydroxy-2′-deoxyguanosine (8-OHdG) and serum malonaldehyde (MDA), total superoxide dismutase (T-SOD), UA (uric acid), interleukin (IL)-6, IL-10, tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), and C-reactive protein (CRP) were measured at baseline, at 6 weeks, and at 12 weeks.

\textbf{Results:} Anthocyanin supplementation (320 mg/day) for 6 weeks significantly improved T-SOD versus baseline (P < 0.05). A slight reduction in serum IL-6, TNF-\(\alpha\), and urine 8-iso-PGF\textsubscript{2\alpha} from the baseline was observed at 12 weeks in the group receiving 40 mg/day anthocyanins. Anthocyanins (80 mg/day) significantly reduced serum IL-6 (−20%), TNF-\(\alpha\) (−11%) and urine 8-iso-PGF\textsubscript{2\alpha} (−27%) versus baseline (P < 0.05). Moreover, 320 mg/day anthocyanin supplementation reduced serum IL-6 (−40%), TNF-\(\alpha\) (−21%), MDA (−20%) and urine 8-iso-PGF\textsubscript{2\alpha} (−37%) and 8-OHdG (−36%) than 80 mg/day and 40 mg/day anthocyanins, P value < 0.05. Anthocyanin supplementation has dose-response relationships with decreased inflammatory cytokines IL-6, TNF-\(\alpha\) and oxidative stress biomarkers 8-iso-PGF\textsubscript{2\alpha}, 8-OHdG and MDA (P for trend, < 0.05). Furthermore, a strong positive correlation was observed between the changes in the urine 8-iso-PGF\textsubscript{2\alpha} and 8-OHdG levels and serum IL-6 levels in subjects from anthocyanin groups after 12 weeks of treatment.

\textbf{Conclusions:} Supplementation of anthocyanins for 12 weeks positively improved the anti-oxidative and anti-inflammatory capacity in a dose–response manner in individuals with dyslipidemia.

\textbf{Abbreviations:} 8-iso-PGF\textsubscript{2\alpha}, 8-isoprostaglandinF\textsubscript{2\alpha}, 8-OHdG, 8-hydroxy-2′-deoxyguanosine; MDA, malonaldehyde; T-SOD, total superoxide dismutase; UA, uric acid; IL-6, interleukin-6; CRP, C-reactive protein; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; CHD, coronary heart disease; BW, body weight; BH, body height; NC, neck circumference; WC, waist circumference; HC, hip circumference; BMI, body mass index; WHR, Waist Hip Ratio; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; FGF, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; VCAM-1, vascular cell adhesion molecule-1; IL-1β, interleukin-1β; IFN-γ, interferon gamma; ROS, reactive oxygen species

∗ Corresponding author. Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong Province, PR China.
∗∗ Corresponding author. Department of Nutrition, School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong Province, PR China.

\textit{E-mail addresses:} zhanghy97@mail2.sysu.edu.cn (H. Zhang), xuzhihuan3@mail2.sysu.edu.cn (Z. Xu), zhaohw5@mail2.sysu.edu.cn (H. Zhao), wangxu25@mail2.sysu.edu.cn (X. Wang), pangj7@mail2.sysu.edu.cn (J. Pang), liqing45@mail2.sysu.edu.cn (Q. Li), yangyan3@mail.sysu.edu.cn (Y. Yang), lingwh@mail.sysu.edu.cn (W. Ling).

https://doi.org/10.1016/j.redox.2020.101474

Received 13 January 2020; Received in revised form 6 February 2020; Accepted 20 February 2020
Available online 26 February 2020

2213-2317/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
1. Introduction

Dyslipidemia, including increased blood total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C), is a global health problem. Recent epidemiologic surveys have revealed that the prevalence of dyslipidemia reached up to 34.0% in Chinese [1,2] and up to 16.58% in Korean adults [3]. Accumulation of these risk factors significantly increases the risk of coronary heart disease (CHD) and its equivalents such as type 2 diabetes and obesity [4–6].

It has been well documented that dyslipidemia results in elevated levels of low-grade inflammatory cytokines, such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and C-reactive protein (CRP) [7,8]. Moreover, serum CRP, IL-6, and TNF-α concentrations have been repeatedly reported to be directly associated with several cardiovascular as well as metabolic diseases [9,10]. Meanwhile, evidence from experimental work indicated a strong association between dyslipidemia and oxidative stress [11–13]. Dyslipidemia lead to the generation of excess free radicals via several biochemical pathways and induce oxidative stress [14]. Oxidative stress can be defined as an imbalance between the production and elimination of reactive oxygen species (ROS). It may favor the oxidation of biomolecules such as lipids, proteins, and DNA, resulting in cell damage and loss of biological function [15]. In this sense, oxidative stress may play a decisive role in the pathogenesis and progression of chronic metabolic diseases [16,17]. Among the many types of ROS-induced oxidative modifications, urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 8-iso-prostaglandin F₂α (8-iso-PGF₂α) have been widely used as sensitive markers of oxidative stress [18,19]. In addition, other biomarkers have been studied to monitor the production of ROS, such as malonaldehyde (MDA) as a surrogate marker of oxidative stress [20]. Furthermore, elevated oxidative stress and inflammation are highly interrelated and cross-promote each other in a vicious cycle, resulting in the progression of CHD outcomes [21]. Therefore, for subjects with dyslipidemia, anti-inflammatory and anti-oxidative therapy has been proposed as a promising and effective strategy for preventing metabolic diseases.

Anthocyanins, a subgroup of flavonoids, are responsible for the production of red-orange to blue-violet pigments in plants (fruits, vegetables, flowers, and grains) [22,23]. Previous human studies have demonstrated that anthocyanin-rich foods or anthocyanin extracts inhibited metabolic diseases owing to their anti-oxidative and anti-inflammatory capacity [24,25]. Among most intervention studies, only a single dose of anthocyanins was used to observe their effect on oxidation and inflammation as well as lipid profile. Thus, the effective dose of anthocyanin supplementation to induce beneficial functions has remained unclear. The aim of this randomized controlled trial was to determine the dose–response effect of anthocyanin supplementation on oxidative and inflammatory response in individuals with dyslipidemia.

2. Subjects and methods

2.1. Subjects

Participants were recruited from local communities in Guangzhou, China, through advertising flyers and clinicians’ recommendations at three community hospitals. Potential participants were interviewed by trained research staff over the telephone or in person with a structured screening questionnaire. Participants with a medical record of hypertension, diabetes, and obesity were further invited to a clinical visit to undergo a serum lipid measurement test to confirm their eligibility (Fig. 1). The inclusion criteria were: (1) men and women aged 35–70 years; (2) dyslipidemia comprising either two or more of the following four criteria [26]: fasting serum TG ≥ 150 mg/dL (1.70 mmol/L), TC ≥ 200 mg/dL (5.20 mmol/L), LDL-C ≥ 120 mg/dL (3.12 mmol/L), or HDL-C ≤ 35 mg/dL (0.91 mmol/L); and (3) less eating out and weight stability in the past 3 months. The exclusion criteria included: (1) taking any medications known to affect lipid metabolism such as statins, currently or within the past 6 months; (2) taking any anthocyanin supplements or anthocyanin-rich foods currently or within the past 2 months; (3) lactating or pregnant women; and (4) suffering from severe acute or chronic illness. The study was approved by the Ethics Committee of Sun Yat-sen University, and informed consent was obtained from each participant before conducting any experiment. The trial was registered at ClinicalTrials.gov (NCT03415503).

2.2. Experimental design

This was a 12-week, randomized, double-blind, placebo-controlled trial with supplementation of multiple doses of anthocyanin. A total of 169 eligible subjects were randomly assigned to one of the four dosing groups: placebo (n = 43), or anthocyanins at 40 (n = 44), 80 (n = 40), or 320 (n = 42) mg/day by a list of random numbers generated by SPSS v22.0 (SPSS Inc., Chicago, IL, USA). Oral capsules with the same weight, appearance, and package were used in three types as 40 or 80 mg anthocyanins (Medox), and placebo capsules. Subjects in four groups were all instructed to consume two capsules twice daily preferably 30-min after breakfast and supper for 12 weeks. In details, subjects in placebo group consumed four placebo capsules, subjects in 40 mg Antho group consumed one 40 mg Medox and three placebo capsules, subjects in 80 mg Antho group consumed one 80 mg Medox and three placebo capsules, and subjects in 320 mg Antho group consumed four 80 mg Medox capsules per day. Subject compliance was assessed by counting the number of returned packages when they received their supplements once every 2 weeks. They were asked to maintain their usual dietary intake and physical activities. The 24-h dietary recall data on 3 consecutive days were collected in the first week, intermediate stage (after 6 weeks), and at the endpoint of our intervention (after 12 weeks). Nutrient intakes were calculated using a computer-aided nutritional analysis program for professionals (Chinese Food Composition Table) [27].

2.3. Study supplements

Medox is a vegetable-encapsulated anthocyanin extracts from wild Norwegian bilberries and blackcurrants manufactured in Norway by MedPalet Pharmaceuticals and the Biolink Group. The Medox capsules contain 80 mg or 40 mg anthocyanins, both of which comprise 17 different natural anthocyanins purified from bilberry (Vaccinium myrtillus) and blackcurrant (Ribes nigrum; refer to Supplemental Tables S1–S3 for the ingredients of anthocyanins capsules). Anthocyanin capsules also contain 4% pullulan, maltodextrin, and citric acid to maintain the stability, whereas the placebo capsules contain only pullulan and maltodextrin [28]. The anthocyanin and placebo capsules have identical weight, appearance, and package.

2.4. Anthropometric analyses

Anthropometric measurements were performed by a trained examiner. Body weight (BW), body height (BH), neck circumference (NC), waist circumference (WC), and hip circumference (HC) were measured according to the standard protocols. Body mass index (BMI) was calculated based on BW and BH: BMI (kg/m²) = BW (kg) / BH² (m²). The waist hip ratio (WHR) was calculated based on WC and HC: WHR (%) = WC (cm) / HC (cm) × 100%. Heart rate and blood pressure (BP), including systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using a validated oscillometric technique (Omron U30 Intellisense, JPN). BP and heart rate were determined in the non-dominant upper arm after a 20-minute resting period on each arm twice. Four values were recorded at 2-minute intervals, and the average of these measures was considered. All measurements were obtained using standardized procedures and periodically calibrated instruments. Individual information was collected by the trained staff via face-to-
face interview based on a structured questionnaire on socio-demo-
graphic data, dietary habits, and living habits.

2.5. Determination of biochemical biomarkers

Overnight fasting (8–10 hour) venous blood samples were collected between 8:00 am and 9:00 am at baseline, and after 6 and 12 weeks. Samples were immediately centrifuged at 3000 rpm for 15 min at 4 °C. Each participant’s serum sample was divided into several aliquots and stored at −80 °C until analysis. First-morning urine sample was collected in two containers and stored at −80 °C until subsequent analyses.

Fasting blood samples were subjected to a complete lipid profile, including LDL-C, HDL-C, TG, TC, apolipoprotein A-1, and apolipoprotein B. Other biochemical analyses included fasting blood glucose (FBG), insulin (FINS), uric acid (UA), and CRP concentrations that were measured using the Cobas c311 automated assay analyzer (c311, Roche Diagnostics, Switzerland). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated based on FBG and FINS:

\[
\text{HOMA-IR} = \frac{\text{FINS (mU/mL)} \times \text{FBG (mmol/L)}}{22.5}
\]

Serum IL-6 was analyzed using commercial kits (catalog no. HS600C, R&D Systems, Minneapolis, USA). Serum IL-10 was assessed using a cytometric cytokine bead array human enhanced sensitivity master buffer kit (catalog no.558274, BD Biosciences, San Jose, CA, USA). Serum TNF-α was determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (catalog no. DP1000, SIEMENS, Munich, Germany). Serum MDA was determined using a commercial ELISA kit (catalog no. S0131, Beyotime, Shanghai, China). The serum total superoxide dismutase (T-SOD) activities were measured using a T-SOD assay kit (catalog no. A001-1-2, Jiancheng, Nanjing, China) and the hydroxylamine method. Urine 8-iso-PGF2α was determined in spot urine samples, because Helmersson and Basu reported that urinary F2-isoprostane isomers concentrations in spot urines showed no significant variation from concentrations measured in 24-hour urine samples in the same healthy individuals by radioimmunoassay [29]. Urine 8-iso-PGF2α was analyzed by competitive enzyme immunoassay (EIA) kit (catalog no.516351, Cayman Chemical Company, Ann Arbor, MI, USA) [30–32]. Urine 8-OHdG was measured using an ELISA Kit (catalog no.CSB-E10140h,

---

Fig. 1. Study participants’ flow diagram.
CISABIO, Wuhan, China). Values for 8-iso-PGF\(_{2\alpha}\) and 8-OHdG were normalized by per milligram of creatinine in urine, which was measured using the Mindray UA-6800 automated assay analyzer (Shenzhen, China).

2.6. Sample size planning

Sample size estimation was conducted using the PASS software (version 11.0, NCSS Inc.). In our previous clinical trial [33], supplementation with 320 mg/day of anthocyanins resulted in a 0.34 nmol/L (13.1 mg/dL) decrease in LDL-C levels relative to the levels in the group treated with placebo. Based on the conventional assumption of a two-tailed \(\alpha\) level of 0.05 and \(\beta\) level of 0.10, it was determined that 38 subjects should be recruited per group. Allowing for a 10% drop-out rate, at least 42 subjects were required in each group.

2.7. Statistical analysis

The data are expressed as mean ± standard error of mean (SEM) unless otherwise stated. Variables with skewed distributions were logarithmically transformed to achieve a normal distribution. The percent change after 6 weeks and 12 weeks were calculated as follows: (value after intervention-value at baseline)/value at baseline \(\times\) 100%. Comparability of the four groups at baseline was assessed by an one-way analysis of variance (ANOVA) and post hoc analysis with Bonferroni correction for multiple comparisons. Student’s \(t\) tests for paired data were used according to assess changes within the group from baseline to follow-up. Differences in the percent change in biomarkers between the intervention groups were analyzed by ANOVA, after logarithmic transformation on the ratio. An extension of the Wilcoxon rank sum test was used to test for linear trends across groups. Pearson correlation coefficients (\(r\)) were calculated to assess the associations between the changes in oxidative stress and inflammatory biomarkers over the 12-week study period. All statistical analyses were two-tailed and performed using SPSS v22.0 (SPSS Inc., Chicago, IL, USA). Statistical significance was set at an \(\alpha\) level of 0.05.

3. Results

3.1. Baseline characteristics and diet monitoring

The baseline characteristics of individuals with dyslipidemia are shown in Table 1. Participants were predominantly females (73.4%) with their age ranging from 35 to 70 years and a BMI of 24.1 kg/m\(^2\) (range: 17.1–33.5 kg/m\(^2\)). Participants in the four groups were comparable in terms of age, gender, smoking status, BW, BMI, NC, WC, WHR, HR, and SBP, except DBP (\(P < 0.05\)). Moreover, the baseline parameters for lipids, glucose, and insulin were comparable among the four study groups.

Dietary intake data at baseline and at the end of 12 weeks are shown in Table 2. There were no significant differences in energy or nutrient intake among four groups. No significant differences were observed between the groups in the daily intake of anthocyanins and vitamins, with anti-oxidative capacity, at baseline and after a 12-week intervention.

3.2. Effects of anthocyanin on serum inflammatory cytokines

The absolute changes in inflammatory cytokines concentration from baseline to follow-up (at 6 and 12 weeks) were assessed within the groups (Fig. 2, Table 3). After 6 weeks, the inflammatory cytokines did not significantly change. After 12 weeks, 40 mg/day anthocyanins moderately reduced the serum IL-6 and TNF\(-\alpha\) from the baseline, but without significance (Fig. 2a and b). However, a 12-week anthocyanin supplementation at 80 mg/day and 320 mg/day significantly decreased the serum IL-6, with baseline 2.71 ± 0.18 pg/mL and 2.34 ± 0.19 pg/mL to final 1.98 ± 0.18 pg/mL and 1.06 ± 0.18 pg/mL, respectively (\(P < 0.05\), Fig. 2a, Table 3), as well as TNF\(-\alpha\), with baseline 6.17 ± 0.25 nmol/L and 6.39 ± 0.55 nmol/L to final 5.39 ± 0.40 nmol/L and 4.92 ± 0.53 nmol/L, respectively (\(P < 0.05\), Fig. 2b, Table 3).

The percent change from baseline to 12 weeks in inflammatory cytokines was compared between the groups (Table 3). Next, we checked whether the serum cytokines levels decreased linearly with the dose of anthocyanin (Fig. 3). The reduction in serum IL-6 from baseline to 12 weeks in both the 80 mg anthocyanin (−20%, \(P < 0.05\)) and 320 mg anthocyanin (−40%, \(P < 0.01\)) groups was significantly different from the change in the placebo group (8%) (Table 3). Similarly, the reduction in serum TNF\(-\alpha\) from the baseline to 12 weeks in the 320 mg anthocyanin group (−21%) was different from the alteration in the placebo group (5%; \(P < 0.01\)) (Table 3). The reduction in IL-6 (\(P \text{ for trend} < 0.001\)) and TNF\(-\alpha\) (\(P \text{ for trend} < 0.01\)) was further found to be significantly dependent on the dose of anthocyanin supplementation (Fig. 3a and b). The percent changes from baseline to 12 weeks in IL-10 and CRP were not significantly different between the groups (Table 3). Interestingly, the alteration of TNF\(-\alpha\) between the 40 mg and 320 mg anthocyanin groups was significantly different at the end of 12 weeks (\(P < 0.05\), Fig. 3b). In addition, the percent change from baseline to 6 weeks in these inflammatory cytokines was not significant between the groups or dependent on the dose of anthocyanin supplementation (Table 3 and Supplemental Fig. 2).

3.3. Effects of anthocyanin on oxidative stress biomarkers

Within groups, the absolute changes in the concentration of oxidative stress biomarkers from baseline to follow-up were assessed. After 6 weeks, a significant increase was observed in the T-SOD activity from 162.68 ± 4.30 U/mL to 178.79 ± 5.21 U/mL (\(P < 0.05\)) in 320 mg anthocyanin group (Table 4). After 12 weeks, subjects receiving 40 mg/day anthocyanins reported moderately reduce of urine 8-iso-PGF\(_{2\alpha}\), but without significance (Fig. 2c, Table 4). The 12-week anthocyanin supplementation at 80 mg/day produced a significant reduction in urine 8-iso-PGF\(_{2\alpha}\), from 1.19 ± 0.07 pg/mg creatinine to 0.89 ± 0.13 pg/mg creatinine (\(P < 0.05\), Fig. 2c, Table 4). Furthermore, 12-week anthocyanin supplementation at 320 mg/day yielded further reduction than 80 mg/day and 40 mg/day dosages for improving urine 8-iso-PGF\(_{2\alpha}\), 8-OHdG, and serum MDA, with baseline 3.13 ± 0.08 pg/mg creatinine, 6.98 ± 0.56 ng/mg creatinine, and 3.78 ± 0.20 μmol/L to post-treatment 1.04 ± 0.16 pg/mg creatinine, 4.25 ± 0.53 ng/mg creatinine, and 2.92 ± 0.18 μmol/L, respectively (\(P < 0.05\), Fig. 2c, d, and 2e, Table 4).

Between groups, percent change was compared and further tested whether oxidative stress biomarkers changed linearly as the dose of anthocyanin increased (Fig. 3 and Table 4). The reduction in urine 8-iso-PGF\(_{2\alpha}\) from baseline to 12 weeks in the 80 mg anthocyanins (−27%, \(P < 0.05\)) and 320 mg anthocyanins (−37%, \(P < 0.01\)) groups was significantly different from the change in the placebo group (21%) (Table 4). Moreover, urine 8-OHdG decreased significantly in the 320 mg anthocyanin group (−36%, \(P < 0.05\)) compared with the alteration in the placebo group (5%) after the 12-week treatment (Table 4). Furthermore, these changes were found to be significantly dependent on the anthocyanin dose (\(P \text{ for trend} < 0.01\) (Fig. 3c and d). Although the percentage change in MDA was not significantly different between groups, there was a significant dose–response effect of the intervention (\(P \text{ for trend} < 0.05\) (Fig. 3e)). However, the percentage changes in T-SOD and UA were not significantly different between the groups, nor was there a significant dose-dependent effect of anthocyanin (Supplemental Figs. 1c and 1d, Table 4). In addition, after 6-week treatment, a significant percent change was observed in the T-SOD activity between anthocyanins group (320 mg/day) and placebo group. Moreover, the change was found to be significantly dependent on the anthocyanin dose (\(P \text{ for trend} < 0.01\) (Supplemental Fig. 2h).
However, other oxidative stress biomarkers did not show significant percent change between groups after 6 weeks (Table 4 and Supplemental Fig. 2).

### 3.4. Association between changes in oxidative stress and inflammation biomarkers

After the 12-week anthocyanin intervention, the decrease in urine 8-iso-PGF\(_2\alpha\) exhibited a positive correlation with the change in serum IL-6.

### Table 1

**Baseline characteristics.**

|                         | Placebo (n = 43) | 40mg Antho (n = 44) | 80mg Antho (n = 40) | 320mg Antho (n = 42) | P value\(^{1}\) |
|-------------------------|------------------|---------------------|---------------------|----------------------|----------------|
| Age, y                  | 56.21 ± 1.01\(^{a}\) | 57.52 ± 1.37        | 58.28 ± 1.17        | 57.41 ± 1.37         | 0.607          |
| Gender (M/F)            | 13/30            | 11/33               | 10/30               | 11/31                | 0.939          |
| Weight (kg)             | 59.17 ± 1.79     | 62.41 ± 1.78        | 59.08 ± 1.64        | 64.92 ± 1.68         | 0.052          |
| CS (%)                  | 3(7.1%)\(^{a}\)  | 4(9.3%)             | 2(5.1%)             | 2(4.8%)              | 0.827          |
| BMI (kg/m\(^2\))        | 24.17 ± 0.39     | 23.77 ± 0.48        | 22.77 ± 0.49        | 24.67 ± 0.57         | 0.514          |
| WC (cm)                 | 84.16 ± 1.85     | 85.14 ± 1.49        | 84.51 ± 1.40        | 86.81 ± 1.49         | 0.642          |
| WBC (% C)               | 0.88 ± 0.02      | 0.89 ± 0.01         | 0.89 ± 0.01         | 0.90 ± 0.01          | 0.674          |
| SBP (mmHg)              | 126.49 ± 2.63    | 117.80 ± 2.38       | 119.85 ± 1.98       | 124.49 ± 2.38        | 0.050          |
| DBP (mmHg)              | 80.55 ± 1.34     | 75.30 ± 1.38        | 75.97 ± 1.31        | 80.15 ± 1.32         | 0.015          |
| BMI (kg/m\(^2\))        | 78.45 ± 1.57     | 75.30 ± 1.65        | 75.81 ± 1.49        | 80.30 ± 1.49         | 0.413          |
| TC (mmol /L)            | 6.11 ± 0.14      | 6.26 ± 0.15         | 6.16 ± 0.14         | 6.35 ± 0.14          | 0.653          |
| HDL-c (mmol /L)         | 4.16 ± 0.15      | 4.29 ± 0.18         | 4.21 ± 0.14         | 4.35 ± 0.13          | 0.838          |
| TG (mmol /L)            | 2.18 ± 0.19      | 2.19 ± 0.27         | 1.95 ± 0.14         | 2.07 ± 0.27          | 0.863          |
| HR                      | 78.45 ± 1.57     | 75.30 ± 1.65        | 75.81 ± 1.49        | 80.30 ± 1.49         | 0.413          |
| DGL (mmol /L)           | 138.74 ± 4.09    | 145.74 ± 3.66       | 150.97 ± 3.12       | 155.97 ± 3.69        | 0.208          |
| WHR (%)                 | 4.13 ± 0.05      | 4.13 ± 0.06         | 4.14 ± 0.07         | 4.13 ± 0.07          | 0.346          |
| CG (%)                  | 5.53 ± 0.28      | 5.38 ± 0.11         | 5.26 ± 0.09         | 5.28 ± 0.13          | 0.710          |
| APOA1 (g/L)             | 11.05 ± 0.96     | 9.56 ± 0.75         | 10.51 ± 1.14        | 10.54 ± 1.39         | 0.544          |

\(^{1}\) P values are for comparison between the four groups (Either a one-way analysis of variance or chi-square test for independent data).

### Table 2

**Daily dietary intakes of total energy and nutrients at baseline and 12 weeks after treatment.**

|                         | Placebo (n = 43) | 40mg Antho (n = 44) | 80mg Antho (n = 40) | 320mg Antho (n = 42) | P value\(^{1}\) |
|-------------------------|------------------|---------------------|---------------------|----------------------|----------------|
| Total energy (kcal/d)   | 1516.65 ± 99.07\(^{a}\) | 1445.86 ± 83.61     | 1580.97 ± 113.86    | 1625.68 ± 100.70    | 0.599          |
| Total energy (kcal/d)   | 1718.84 ± 93.65  | 1501.20 ± 96.56     | 1535.59 ± 142.07    | 1552.08 ± 86.34     | 0.458          |
| Total protein (g/d)     | 68.74 ± 4.09     | 70.53 ± 3.46        | 74.00 ± 5.06        | 81.30 ± 5.26        | 0.208          |
| Total protein (g/d)     | 79.42 ± 4.20     | 72.91 ± 4.17        | 74.69 ± 10.36       | 76.94 ± 3.99        | 0.880          |
| Total lipids (g/d)      | 49.28 ± 3.37     | 45.62 ± 3.09        | 46.55 ± 6.02        | 56.53 ± 5.80        | 0.299          |
| Total lipids (g/d)      | 58.67 ± 4.24     | 46.36 ± 3.90        | 54.12 ± 8.14        | 45.61 ± 3.84        | 0.219          |
| Cholesterol (mg/d)      | 440.30 ± 40.08   | 434.78 ± 30.82      | 421.51 ± 38.26      | 534.32 ± 40.59      | 0.054          |
| Cholesterol (mg/d)      | 471.33 ± 31.90   | 421.46 ± 40.05      | 532.73 ± 40.43      | 460.35 ± 41.86      | 0.717          |

\(^{1}\) P values are for comparison between the four groups at baseline and after 12 weeks of intervention (A one-way analysis of variance for independent data).
In this randomized controlled trial, we observed a linear dose–response relationship for the change in inflammatory and oxidative biomarkers after anthocyanin supplementation in individuals with dyslipidemia. At 12 weeks, anthocyanin supplementation at 40 mg/day moderately reduced serum IL-6 and TNF-α and urine 8-iso-PGF₂α. Supplementation of anthocyanins 80 mg/day for 12 weeks produced significant reduction in IL-6 and TNF-α and 8-iso-PGF₂α. Subjects who received 320 mg/day anthocyanins for 12 weeks showed further improvement in reducing serum IL-6 and TNF-α, MDA, and urine 8-iso-PGF₂α, 8-OHdG than those who received 80 mg/day and 40 mg/day anthocyanins. In addition, 6-week anthocyanin supplementation at
320 mg/day significantly improved T-SOD, but no other cytokines. These results revealed the dose-response of anthocyanin-induced anti-inflammatory and anti-oxidative effects. Moreover, these results indicated that anthocyanin supplementation at 80 mg/day could reach the threshold level for producing beneficial functions among subjects with dyslipidemia.

A number of studies reported that consumption of anthocyanin-rich foods such as berries (raspberries [34], bilberry juice [35], and blueberries [36]) as well as anthocyanin extracts [37,38] resulted in beneficial functions such as decreasing inflammatory and oxidative stress biomarkers, improving glucose and fatty acid metabolism, as well as improving vascular endothelial functions [39]. However, the effective dose of anthocyanin at which it exerts beneficial functions has not been well studied. Despite the widely variant anthocyanin doses in previous intervention studies, ranging from 59.5 mg/day [40] to 640 mg/day [41], most studies only used a single dose to observe the effect of anthocyanins. For example, Traustadottir et al. [40] reported that intake of 240 mL tart cherry juice twice daily (59.5 mg of total anthocyanins per day) for 4 weeks reduced urine 8-OHdG and plasma F2-isoprostane compared with the levels in subjects in the placebo group. However, another trial with similar dose and conducted by Estevez-Santiago [42] showed that 8-month anthocyanin supplementation at 60 mg/day improved none of the plasma CRP, IL-6, vascular cell adhesion molecule-1 (VCAM-1), or intercellular adhesion molecule-1 in postmenopausal women. Previous trial [43] with supplementation of 320 mg/day anthocyanins showed significant reduction in UA but not in CRP after 24 weeks in adults with prediabetes. The supplementation of anthocyanins 640 mg/day for 4 weeks significantly improved serum concentrations of HDL and blood glucose, but no effects on the inflammatory or oxidative stress biomarkers in pre-hypertensive men [41] were observed. Taken together, these studies with inconsistent results used a single dose of anthocyanins and their study designs largely varied, with differences in intervention duration and the studied population, which hindered the comparison of effects between different anthocyanin levels. Therefore, there exists no evidence to raise the concentration of anthocyanins to adequate levels to improve the health status and prevent or treat metabolic diseases. The present study first assessed the dose-response effect of anthocyanins and demonstrated that anthocyanins at 80 mg/day could produce beneficial functions by improving inflammation and oxidative stress among subjects with dyslipidemia, whereas 320 mg/day anthocyanins would result in obvious improvement in inflammatory and oxidative response. This evidence indicated that a daily intake of 80 mg or more of anthocyanins could be recommended as a therapeutic strategy for dyslipidemia.

Observational studies across countries showed that anthocyanin intake in daily diet was relatively low, ranging from 11.48 to 47.0 mg/day. For example, Finnish [44] consumed anthocyanin 47.0 mg/day from their daily diet, which was higher than those consumed by other adults in Korea [45] (37.0 mg/day), France [46] (35.0 mg/day), China [47] (28.0 mg/day), Australia [48] (24.17 mg/day), Spain [49] (18.8 mg/day), and America [50] (11.48 mg/day). Taken together, anthocyanins intake from daily diet in these countries did not reach 80 mg, which was recommended to exert beneficial functions in our trial. Thus, supplementation with adequate amounts of anthocyanins, for example in the form of anthocyanin-rich food or anthocyanin extracts, appeared necessary. Actually, it is not difficult to meet the anthocyanin supplementation at 80 mg/day with food rich in anthocyanins, especially berries and currants. For example, anthocyanins content ranges from 295.48 mg to 1266.00 mg in every 100 g black elderberry [51,52], 125.63 mg–989.70 mg in every 100 g black chokeberry [51,53], and 85.21 mg–190.62 mg per 100 g blackberry [54]. Therefore, anthocyanin supplementation at 80 mg/day appears both clinical relevant and realizable by food.

In addition to adequate levels of anthocyanin intake, the duration of anthocyanin supplementation plays an important role in preventing metabolic diseases. In the present trial, we found that the intervention effects for 6 weeks were not as significant as those at 12 weeks, with improving only CRP and T-SOD but no other biomarkers. A linear dose-response relationship was not observed after 6 weeks either. It indicated that adequate intervention duration was important. Wright et al. [55] reported that 4-week supplementation with dried purple carrot (118.5 mg/day anthocyanins) showed no significant decrease in BMI, body composition, appetite, LDL-C, TC, or CRP in overweight and obese adults. Another short-term trial conducted by Karlson et al. [56] showed that 3-week intake of purified anthocyanins (300 mg/day) did not result in significant alterations in CRP, TNF-α, or interleukin-1β (IL-1β) concentrations in healthy adults. However, a long-term intervention trial with similar anthocyanin levels conducted by Zhu et al. [57]

| Table 3 | Effects of anthocyanin on inflammatory biomarkers. |
|---------|---------------------------------------------------|
|         | Value (n = 43) | Value (n = 44) | Value (n = 40) | Value (n = 42) |
|         | Placebo | 40mg Antho | 80mg Antho | 320mg Antho |
| **IL-6 (pg/mL)** | **Baseline** | **6 wk** | **12 wk** | **Baseline** | **6 wk** | **12 wk** | **Baseline** | **6 wk** | **12 wk** |
|        | 2.30 ± 0.21 | 2.50 ± 0.25 | 2.29 ± 0.28 | 6.02 ± 0.39 | 5.65 ± 0.39 | 5.69 ± 0.35 | 6.62 ± 0.39 | 1.23 ± 0.10 | 1.01 ± 0.09 | 1.09 ± 0.09 |
|        |           | 2.92 ± 0.14 | 2.83 ± 0.17 | 2.77 ± 0.25 | 6.76 ± 0.38 | 6.39 ± 0.47 | 6.52 ± 0.42 | 1.11 ± 0.09 | 0.99 ± 0.09 | 1.04 ± 0.08 |
|        |           | 0.04 ± 0.07 |          | -0.04 ± 0.08 | -0.02 ± 0.06 | -0.02 ± 0.05 | -0.11 ± 0.06 | 0.14 ± 0.07 | 0.18 ± 0.12 | 0.13 ± 0.08 |**|**
|        |           |          |          |          |          |          |          |          |          |          |
| **CRP (mg/L)** | **Baseline** | **6 wk** | **12 wk** | **Baseline** | **6 wk** | **12 wk** | **Baseline** | **6 wk** | **12 wk** |
|        | 1.42 ± 0.16 | 1.33 ± 0.14 | 1.53 ± 0.25 | 1.42 ± 0.16 | 1.46 ± 0.17 | 1.52 ± 0.25 | 1.46 ± 0.17 | 1.38 ± 0.17 | 1.29 ± 0.17 | 1.52 ± 0.25 |**|**
|        |          | 0.08 ± 0.07 | 0.12 ± 0.09 | 0.12 ± 0.09 | 0.04 ± 0.06 | 0.04 ± 0.06 | 0.04 ± 0.06 | 0.13 ± 0.08 | 0.03 ± 0.07 | 0.10 ± 0.12 |**|**
|        |          |          |          |          |          |          |          |          |          |          |
| **IL-10 (pg/ml)** | **Baseline** | **6 wk** | **12 wk** | **Baseline** | **6 wk** | **12 wk** | **Baseline** | **6 wk** | **12 wk** |
|        | 6.02 ± 0.39 | 5.65 ± 0.39 | 5.69 ± 0.35 | 6.62 ± 0.39 | 1.23 ± 0.10 | 1.01 ± 0.09 | 1.09 ± 0.09 | 1.11 ± 0.09 | 1.14 ± 0.07 | 1.13 ± 0.12 | 1.20 ± 0.06 |**|**
|        |          | 6.76 ± 0.38 | 6.39 ± 0.47 | 6.52 ± 0.42 | 0.99 ± 0.09 | 0.99 ± 0.09 | 1.04 ± 0.08 | 0.11 ± 0.09 | 0.18 ± 0.12 | 0.13 ± 0.08 |**|**
|        |          |          |          |          |          |          |          |          |          |          |
| **MC (%)** |          |          |          |          |          |          |          |          |          |          |**|**

1 Compared within the group from baseline to follow-up (Either Wilcoxon signed rank test or Students’ t test for paired data), *P < 0.05.
2 Compared between the placebo group and anthocyanin groups (ANOVA for independent data), $P < 0.05$, **P < 0.01.

Abbreviation: SEM, standard error of mean; MC, mean change; Antho, anthocyanin group; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; IL-10: interleukin-10; CRP, C-reactive protein.

a Mean ± SEM (all such values).

b Calculated as (value after intervention-value before intervention) / value before intervention × 100 %.
reported that purified anthocyanin supplementation at 320 mg/day significantly reduced CRP, VCAM-1, and IL-1β concentrations in subjects with hypercholesterolemia at 12 and 24 weeks after intervention [69]. Similarly, another 12-week intervention study showed that anthocyanin-rich beverage significantly improved biomarkers for inflammation and oxidative stress, including plasma interferon gamma (IFN-γ) and urine 8-isoprostanate concentration in individuals with metabolic syndrome. It might be possible that the efficacy of anthocyanin on inflammatory, oxidative stress, lipids, and other responses depends on, to some extent, the duration of the intervention.

Dyslipidemia is associated with elevated levels of reactive oxygen species (ROS), biomarkers of lipid peroxidation, DNA oxidation, and pro-inflammatory cytokines [8,58–60]. Evidence suggests that oxidative stress, as an active contributor to the early steps of metabolic diseases, is primarily attributed to the pathologic role of ROS in visceral adiposity, endothelial damage, and lipoprotein metabolism [61,62]. Pro-inflammatory cytokines, including CRP, IL-6, and TNF-α, have been repeatedly reported to be directly associated with several cardiovascular, as well as metabolic diseases [9,10], by activation of NF-κB and MAPK signaling pathways [63,64]. Meanwhile, oxidative stress can also

Fig. 3. Percentage change in biomarker concentration after the 12-week intervention. Percentage change was compared between groups and linear trend analysis was further assessed. Data represent the mean (SEM) measurements for each group. *P < 0.05; **P < 0.01 and ***P < 0.001 between anthocyanins groups and placebo group as well as linear trend analysis; †P < 0.05 between 320 mg/day and 40 mg/day anthocyanins group. SEM, standard error of mean; IL-6, interleukin-6; TNF-α, tumor necrosis factor α; 8-iso-PGF2α, 8-isoprostaglandin F2α; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; MDA, malonaldehyde; Antho, anthocyanin group.
Table 4
Effects of anthocyanin on oxidative stress biomarkers.

|                        | Placebo (n = 43) | 40mg Antho (n = 44) | 80mg Antho (n = 40) | 320mg Antho (n = 42) |
|------------------------|------------------|---------------------|---------------------|----------------------|
| **Baseline**           |                  |                     |                     |                      |
| Urine 8-iso-PGF_2α (ng/mg creatinine) |                  |                     |                     |                      |
| Baseline               | 1.26 ± 0.07      | 1.27 ± 0.06         | 1.19 ± 0.07         | 1.31 ± 0.08          |
| 6 wk                   | 1.22 ± 0.10      | 1.18 ± 0.12         | -0.02 ± 0.10        | 1.22 ± 0.13          |
| 12 wk                  | 1.44 ± 0.12      | 1.18 ± 0.09         | -0.05 ± 0.07        | 0.89 ± 0.13          |
| **Urine 8-OHdG (ng/mg creatinine)** |                  |                     |                     |                      |
| Baseline               | 5.81 ± 0.48      | 6.16 ± 0.49         | 6.12 ± 0.43         | 6.98 ± 0.56          |
| 6 wk                   | 5.31 ± 0.45      | 5.63 ± 0.47         | 5.82 ± 0.44         | 6.55 ± 0.55          |
| 12 wk                  | 5.61 ± 0.47      | 5.91 ± 0.49         | 5.74 ± 0.42         | 4.25 ± 0.53          |
| MDA (μmol/L)           |                  |                     |                     |                      |
| Baseline               | 3.52 ± 0.16      | 3.71 ± 0.19         | 3.62 ± 0.19         | 3.78 ± 0.20          |
| 6 wk                   | 3.57 ± 0.20      | 3.61 ± 0.23         | 3.21 ± 0.21         | 3.37 ± 0.21          |
| 12 wk                  | 3.41 ± 0.17      | 3.62 ± 0.23         | 3.20 ± 0.20         | 2.92 ± 0.18          |
| T-SOD (U/ml)           |                  |                     |                     |                      |
| Baseline               | 162.80 ± 3.61    | 166.52 ± 3.80       | 166.56 ± 3.35       | 162.68 ± 4.30        |
| 6 wk                   | 168.02 ± 3.49    | 171.55 ± 3.89       | 171.28 ± 4.10       | 178.79 ± 5.21        |
| 12 wk                  | 161.48 ± 3.26    | 165.99 ± 3.84       | 165.78 ± 3.05       | 162.76 ± 3.76        |
| UA (μmol/L)            |                  |                     |                     |                      |
| Baseline               | 367.65 ± 17.54   | 367.01 ± 15.07      | 367.46 ± 12.81      | 361.21 ± 16.96       |
| 6 wk                   | 349.80 ± 15.44   | 347.21 ± 19.27      | 328.73 ± 16.96      | 339.73 ± 18.38       |
| 12 wk                  | 392.70 ± 17.22   | 392.97 ± 20.53      | 354.62 ± 14.53      | 370.43 ± 16.90       |

1 Compared within the group from baseline to follow-up (Either Wilcoxon signed rank test or Students’ t test for paired data), *P < 0.05.
2 Compared between the placebo group and anthocyanin groups (ANOVA for independent data), **P < 0.01.
Abbreviation: SEM, standard error of mean; MC, mean change; Antho, anthocyanin group; 8-iso-PGF_2α, 8-iso-prostaglandin F_2α; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; MDA, malonaldehyde; T-SOD: total superoxide dismutase; UA, uric acid.

Funding

This work was supported by Grant 81730090 from the Key Project of National Natural Science Foundation of China and the Guangzhou Science, Technology and Innovation Committee (Grant. 201804020045).

Authors’ contributions

The authors made the following contributions: HY.Z., ZL.X. and X.W. conducted the experiments; HW.Z. managed the overall project, and wrote the manuscript. HY.Z. contributed to the project design and the manuscript. ZL.X., HW.Z., X.W., and HY.Z. contributed to summarizing and calculating the raw data and revising the manuscript. The authors have nothing to disclose.

Declaration of competing interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the results presented in the manuscript entitled.

Acknowledgements

The treated capsules, including the anthocyanin (Medox) and the placebo, were kindly donated by MedPalett Pharmaceuticals and the Biolink Group in Norway.
Fig. 4. Correlation between changes in oxidative stress and inflammation biomarkers. Association between the change in serum IL-6 levels and the alteration in urine 8-iso PGF2α levels are shown in Fig. 4a and c; and the decrease in urine 8-OHdG are shown in Fig. 4b and d. Pearson’s correlation coefficients are noted for each plot. Fig. 4a and b represent the anthocyanin groups (n = 126), whereas Fig. 4c and d represent the placebo group (n = 43). 8-iso-PGF2α, 8-iso-prostaglandin F2α; 8-OHdG, 8-hydroxy-2′-deoxyguanosine; IL-6, interleukin-6.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2020.101474.

References

[1] L. Pan, Z.H. Yang, Y. Wu, R.X. Yin, Y.H. Liao, J.W. Wang, B.X. Gao, L.X. Zhang, C.K.D.W. Grp, The prevalence, awareness, treatment and control of dyslipidemia among adults in China, Atherosclerosis 248 (2016) 2–9.
[2] W.Y. Yang, J.Z. Xiao, Z.J. Yang, L.N. Ji, W.P. Jia, J.P. Weng, J.M. Lu, Z.Y. Shan, J. Liu, H.M. Tian, Q.H. Ji, D.L. Zhu, J.P. Ge, L.X. Lin, L. Chen, X.H. Guo, Z.G. Zhao, Q. Li, Z.G. Zhou, G.L. Shan, J. He, C.N.D.M. Disorders, Serum lipids and lipoproteins in Chinese men and women, Circulation 125 (2012) 2212–2221.
[3] S. Boo, Y.J. Yoon, H. Oh, Evaluating the prevalence, awareness, and control of hypertension, diabetes, and dyslipidemia in Korea using the NHIS-NSC database A cross-sectional analysis, Medicine 97 (2018).
[4] M. Von Eynatten, A. Hamann, D. Twardella, P.P. Nawroth, H. Brenner, D. Rothenbacher, Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease, Clin. Chem. 52 (2006) 853–859.
[5] A.D. Mooradian, Dyslipidemia in type 2 diabetes mellitus, Nat. Rev. Endocrinol. 5 (2009) 150–159.
[6] B. Klop, J.W.F. Elts, M.C. Cabezas, Dyslipidemia in obesity: mechanisms and potential targets, Nutrients 5 (2013) 1218–1240.
[7] G.C. Brooks, M.J. Blaha, R.S. Blumenthal, Relation of C-reactive protein to abdominal adiposity, Am. J. Cardiol. 106 (2010) 56–61.
[8] D.L. Sparks, C. Chatterjee, Purinergic signaling, dyslipidemia and inflammatory disease, Cell. Physiol. Biochem. 30 (2012) 1333–1339.
[9] P.D. Loprinzi, M.K. Edwards, CVD-related Fit-Fat Index on inflammatory-based CVD biomarkers, Int. J. Cardiol. 223 (2016) 284–285.
[10] C.N. Lumeng, A.R. Saltiel, Inflammatory links between obesity and metabolic disease, J. Clin. Invest. 121 (2011) 2111–2117.
[11] Y.S. Diniz, K.K.H.R. Rocha, G.A. Soura, C.M. Gallhardi, G.M.X. Ebaid, H.G. Rodrigues, J.L.V.B. Novelli, A.C. Caicogna, E.L.B. Novelli, Effects of N-acetyl-
[12]–ylcysteine on sucrose-rich diet-induced hyperglycaemia, dyslipidemia and oxidative stress in rats, Eur. J. Pharmacol. 543 (2006) 151–157.
[13] G. Anzuzi, L. Buzzetto, G. Costabile, R. Giacco, A. Mangione, G. Anniballi, M. Vitale, C. Vetrani, P. Cipriano, G. Della Corte, P. Pasanisi, G. Riccardi, A.A. Rivellese, Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia and reduce oxidative stress: a randomized controlled trial(1–3), Am. J. Clin. Nutr. 99 (2014) 463–471.
[14] A. Gomez-Garcia, G.M. Torres, L.E. Ortega-Pierres, A. Sahebkar, Oxidative burden and oxidative stress modulation, Adv. Clin. Chem. 68 (2015) 87–159.
[15] J.Y. Kim, J.W. Lee, Y.J. Youn, M.S. Ahn, S.G. Ahn, B.S. Yoo, S.H. Lee, J. Yoon, K.H. Choe, Urinary levels of 8-iso-prostaglandin F2α, 8-OHdG, 8-hydroxy-2′-deoxyguanosine; IL-6, interleukin-6.
L.P. Yang, W.H. Ling, Y. Yang, Y.M. Chen, Z.Z. Tian, Z.C. Du, J.Y. Chen, Y.L. Xie, J.M. Koponen, A.M. Happonen, P.H. Mattila, A.R. Torronen, Contents of anthocyanins and ellagitannins in selected foods consumed in Finland, J. Agric. Food Chem. 55 (2007) 1612–1619.

C. Manach, A. Scalbert, C. Morand, C. Remeys, J. Jimenez, Polyphenols: food sources and bioavailability, Am. J. Clin. Nutr. 79 (2004) 727–740.

S. Zafra-Stone, T. Yasmin, M. Bagchi, A. Chatterjee, J.A. Vinson, D. Bagger, Berry anthocyanins as novel antioxidants in human health and disease prevention, Mol. Nutr. Food Res. 51 (2007) 675–683.

M. Kolesárová, O. Mykkanen, P.K. Virjavainen, T. Leppanen, E. Moilanen, M. Adriaens, D.E. Laaksonen, M. Hallikainen, R. Puupponen-Pimiä, L. Pulkkinen, H. Mykkänen, H. Gylling, K. Poutanen, R. Torronen, Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome, Mol. Nutr. Food Res. 56 (2012) 1501–1510.

R. Franssen, H. Monajemi, E.G.S. Stroe, J.J.P. Kastelein, Obesity and dyslipidemia, J. Clin. Nutr. 95 (2011) 892.

L. Lu, D. Yu, H. Fang, Q. Guo, X. Su, L. Zhao, Trends and food sources composition of energy, protein and fat in Chinese residents, 1992–2012, Wei Sheng Yan Jiu 47 (2018) 698–704.

W. Q. Zhao, J. Zhang, M. Xia, The anthocyanin cyanidin-3-O-beta-glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: involvement of a cAMP-PKA-dependent signaling pathway, Free Radic. Biol. Med. 52 (2012) 314–327.

J. Helmersson, S. Basu, F-2-isoprostane excretion rate and diurnal variation in human serum, Prostaglandins 61 (2001) 1079–1087.

H. Shibata, T. Nabika, H. Moriyama, J. Masuda, S. Kobayashi, Correlation of NO metabolites and antioxidant parameters with F-2-isoprostane levels in the urine of children receiving valproic acid, J. Pediatr. 149 (2006) 692–696.

M. Adriaens, D.E. Laaksonen, M. Hallikainen, R. Puupponen-Pimiä, L. Pulkkinen, H. Mykkänen, H. Gylling, K. Poutanen, R. Torronen, Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome, Mol. Nutr. Food Res. 56 (2012) 1501–1510.

S. Sniehotta, F. Sniehotta, T. Schneider, D. Sniehotta, A randomized controlled trial of the effect of dried purple carrot on body mass, lipid, blood pressure, body composition, and inflammatory markers in overweight and obese women: the QO-Cherry trial, Nutr. Metab. Cardiovasc. Dis. 23 (2013) 843–849.

M. Johnson, E.G. de Mejia, Comparison of chemical composition and antioxidant capacity of commercially available blueberry and blackberry wines in Illinois, J. Food Sci. 77 (2012) C141–C148.

E.O. Wright, G.A. Netzel, A.A. Sakzewski, A randomized, double-blind, placebo-controlled trial of the effect of dried purple carrot on body mass, lipid, blood pressure, body composition, and inflammatory markers in overweight and obese women: the QO-Cherry trial, Nutr. Metab. Cardiovasc. Dis. 23 (2013) 843–849.

H. Zhang, et al., J. Perez-Jimenez, L. Fezeu, M. Touvier, N. Arnault, C. Manach, S. Hercberg, Dietary intake and major food sources of polyphenols in Finnish adults, Nutr. Metab. 13 (2016) 86.

P. Mattila, Dietary intake and major food sources of polyphenols in Finnish adults, Nutr. Metab. 13 (2016) 86.

J. Helmersson, S. Basu, F-2-isoprostane excretion rate and diurnal variation in human serum, Prostaglandins 61 (2001) 1079–1087.

M. Adriaens, D.E. Laaksonen, M. Hallikainen, R. Puupponen-Pimiä, L. Pulkkinen, H. Mykkänen, H. Gylling, K. Poutanen, R. Torronen, Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome, Mol. Nutr. Food Res. 56 (2012) 1501–1510.

S. Sniehotta, F. Sniehotta, T. Schneider, D. Sniehotta, A randomized controlled trial of the effect of dried purple carrot on body mass, lipid, blood pressure, body composition, and inflammatory markers in overweight and obese women: the QO-Cherry trial, Nutr. Metab. Cardiovasc. Dis. 23 (2013) 843–849.

M. Matsuda, I. Shimomura, Increased oxidative stress in obesity: implications for metabolic syndrome, obesity, and type 2 diabetes, J. Nutr. 138 (2008) 562–566.

J. Perez-Jimenez, L. Fezeu, M. Touvier, N. Arnault, C. Manach, S. Hercberg, Dietary intake and major food sources of polyphenols in Finnish adults, Nutr. Metab. 13 (2016) 86.